The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brian Abrahams - RBC Capital Markets - Analyst
: Hey. Good morning. Thanks so much for taking my question. I'm curious on LEQEMBI, when you might expect to see more pull
through from the expanded commercial efforts, whether you're starting to see any of those signals in October.
And you mentioned as well the potential for some other commercial acceleration strategies in your prepared remarks. Can you
maybe expand on that a little bit more and characterize your overall alignment with Eisai on the commercial plans? Thanks.
Question: Phil Nadeau - TD Cowen - Analyst
: Good morning. Thanks for taking our question. Chris, you've referenced the subcutaneous formulation a couple of times already
this morning. Could you give us a bit more of an update on the status of the subcu filings both for maintenance as well as for
induction? Thanks.
Question: Marc Goodman - Leerink Partners - Analyst
: Yes. Could you comment a little bit more on SKYCLARYS (inaudible) US. There was a comment in the opening remarks about pricing
and reimbursement dynamics. And if you could just give us a little more color there to the challenges. Thank you.
Question: Salveen Richter - Goldman Sachs & Company, Inc. - Analyst
: Thank you. Good morning. Chris, you spoke to the efforts with regard to the late-stage pipeline in R&D, but you've also noted the
lever with regard to business development. Any updated thoughts here as to the strategy for the latter on the forward?
Question: Michael Yee - Jefferies LLC - Analyst
: Thank you. Good morning. We noticed that you completed the enrollment of the AHEAD 3-45 study. And I just wanted to ask Priya,if
you could remind us what the timeline would look for that, more specifically, if there is a potential for an interim analysis and/or
what that would be based on?
My understanding is that these are pretty early presymptomatic patients. Is there an enrichment of the population? And why would
you be expecting that this can be positive? Thank you.
Question: Umer Raffat - Evercore ISI - Analyst
: Hi, guys. Thanks for taking my questions. I thought I'll focus on a slightly different topic for a quick second. It does look like there's
a very significant amount of R&D investment going into lupus between your dapirolizumab as well as your BDCA molecule and
possibly the CD38 as well.
And I guess my broader question is this. You hit a Phase 3, which is obviously good news. But separately, we're seeing incredible
remission data from some CD19 CAR-Ts, which might even possibly manifest in some CD19 bispecifics as well.
So it seems like you have a lot of exposure, not on that area, which is CD19 bispecific. And I guess, how should we weigh by the time
you guys do get to this market relative to some of the emerging data from potentially CD19 bispecific or the T cell engagers? Thank
you very much.
Question: Jay Olson - Oppenheimer & Co., Inc. - Analyst
: Hey, congrats on the quarter and thank you for taking the questions. We're curious about the $14 billion of peak revenue potential
from your four key pipeline programs. Can you talk about the relative contribution and timing of the four products in terms of which
ones are the largest and nearest term? Thank you.
Question: Evan Seigerman - BMO Capital Markets - Analyst
: Hi, guys. Thank you so much for taking my questions. I know in the past, we've talked about the potential for SPINRAZA returning
to growth. Given the softer numbers this quarter, can you just talk about how you think that this is achieved. Is it predicated on high
dose nusinersen? Or are there other factors and levers that you can pull to accelerate -- reaccelerate the growth of this product?
Thank you.
Question: Paul Matteis - Stifel Nicolaus and Company, Incorporated - Analyst
: Hey. Thanks very much for taking the question. In connecting some of the dots here, Chris, as it relates to the hires you've made and
some of your portfolio decisions around certain legacy high-risk assets, it feels like more and more Biogen is bolstering its expertise
in neurology and maybe shifting away from neurology.
Is that the right way we should think about things going forward? In other words, when you look at business development, do you
have any appetite any more to take on risk in neuroscience? Or do you feel like immunology, rare areas that you have a lot of
experience with historically are going to be the sweet spot going forward? Thanks.
Question: Terence Flynn - Morgan Stanley - Analyst
: Thanks for taking the question. Mike, I was just wondering if you can help us think directionally about margins for 2025 and some
of the puts and takes. Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 30, 2024 / 12:30PM, BIIB.OQ - Q3 2024 Biogen Inc Earnings Call
| 
